Investment Analysts’ Weekly Ratings Updates for Guardian Pharmacy Services (GRDN)

A number of firms have modified their ratings and price targets on shares of Guardian Pharmacy Services (NYSE: GRDN) recently:

• 10/25/2026 – Guardian Pharmacy Services was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/23/2026 – Guardian Pharmacy Services was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 10/17/2026 – Guardian Pharmacy Services was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/8/2026 – Guardian Pharmacy Services was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 9/22/2026 – Guardian Pharmacy Services is now covered by KeyCorp. They set an “overweight” rating and a $52.00 price target on the stock.
• 9/22/2026 – Guardian Pharmacy Services was given a new $52.00 price target by KeyCorp. They now have an “overweight” rating on the stock.
• 9/22/2026 – Guardian Pharmacy Services is now covered by KeyCorp. They set an “overweight” rating and a $52.00 price target on the stock.
• 9/21/2026 – Guardian Pharmacy Services had its price target raised by Truist Financial from $47.00 to $51.00. They now have a “buy” rating on the stock.
• 9/19/2026 – Guardian Pharmacy Services was downgraded by Wall Street Zen from “buy” to “hold”.

Guardian Pharmacy Services, Inc is a provider of pharmacy services focused primarily on residents of long-term care and other institutional healthcare settings. Through its network of pharmacies, the company supplies prescription medications and related pharmacy support to assisted living communities, skilled nursing facilities, behavioral health organizations, and other care providers.

The company’s services include medication dispensing and packaging, prescription delivery, medication management, clinical pharmacy support, and technology-enabled tools designed to help caregivers and healthcare professionals manage residents’ medication regimens.